R&D Views & Analysis | pharmaphorum

Views & Analysis

R&D

Changing Faces – Boards of Directors and Advisory Boards – A...

Welcome back to Changing Faces, in our final round-up for August and September there are plenty of Board appointments to report on.

R&D

Reimagining biopharma: How AI is reshaping discovery, develo...

No longer confined to experimental pilots, AI is becoming a catalyst for change across the entire biopharma value chain - but there are challenges.

R&D

How a century-old technology could revolutionise LNP charact...

The utility of AUC in LNP characterisation is growing, thanks to ongoing efforts to improve the technology.

R&D

Staying on course: How hybrid FSP/FSO models are shaping cli...

Biotech and pharma companies increasingly require additional agility, flexibility, and operational efficiency in their clinical research operations.

R&D

Bolstering CAR-T therapies by tackling CRS, with Teresa Whal...

In interview with Teresa Whalen, the CEO of CytoAgents, a clinical-stage drug development company working on a treatment for cytokine release syndrome

R&D

pharmaphorum podcast Episode 209a, Gene Mack

Allosteric small molecule therapies in PD, with Gene Mack

pharmaphorum looks back to a conversation with Gain Therapeutics' CEO Gene Mack earlier in the year, on research in the Parkinson's disease space.